Systemic acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis

Melissa Tully, Jonathan Tang, Lingxing Zheng, Glen Acosta, Ran Tian, Lee Hayward, Nicholas Race, David Mattson, Riyi Shi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, due to the invasive nature of acrolein detection using immunoblotting techniques, the investigation of acrolein in MS has been limited to animal models. Recently, detection of a specific acrolein-glutathione metabolite, 3-HPMA, has been demonstrated in urine, enabling the noninvasive quantification of acrolein for the first time in humans with neurological disorders. In this study, we have demonstrated similar elevated levels of acrolein in both urine (3-HPMA) and in spinal cord tissue (acrolein-lysine adduct) in mice with EAE, which can be reduced through systemic application of acrolein scavenger hydralazine. Furthermore, using this approach we have demonstrated an increase of 3-HPMA in both the urine and serum of MS patients relative to controls. It is expected that this noninvasive acrolein detection could facilitate the investigation of the role of acrolein in the pathology of MS in human. It may also be used to monitor putative therapies aimed at suppressing acrolein levels, reducing severity of symptoms, and slowing progression as previously demonstrated in animal studies.

Original languageEnglish (US)
Article number420
JournalFrontiers in Neurology
Volume9
Issue numberJUN
DOIs
StatePublished - Jun 15 2018

Fingerprint

Acrolein
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
hydroxypropyl methacrylate
Urine
Oxidative Stress
Animal Models
Hydralazine
Neurotoxins
Demyelinating Diseases
Pathologic Processes
Nervous System Diseases
Immunoblotting
Lysine
Glutathione
Spinal Cord

Keywords

  • 3-HPMA
  • Aldehyde
  • Inflammation
  • Lipid peroxidation
  • Oxidative stress

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Systemic acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis. / Tully, Melissa; Tang, Jonathan; Zheng, Lingxing; Acosta, Glen; Tian, Ran; Hayward, Lee; Race, Nicholas; Mattson, David; Shi, Riyi.

In: Frontiers in Neurology, Vol. 9, No. JUN, 420, 15.06.2018.

Research output: Contribution to journalArticle

Tully, Melissa ; Tang, Jonathan ; Zheng, Lingxing ; Acosta, Glen ; Tian, Ran ; Hayward, Lee ; Race, Nicholas ; Mattson, David ; Shi, Riyi. / Systemic acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis. In: Frontiers in Neurology. 2018 ; Vol. 9, No. JUN.
@article{9a389615f0af4b648ee66c537d7f564f,
title = "Systemic acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis",
abstract = "Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, due to the invasive nature of acrolein detection using immunoblotting techniques, the investigation of acrolein in MS has been limited to animal models. Recently, detection of a specific acrolein-glutathione metabolite, 3-HPMA, has been demonstrated in urine, enabling the noninvasive quantification of acrolein for the first time in humans with neurological disorders. In this study, we have demonstrated similar elevated levels of acrolein in both urine (3-HPMA) and in spinal cord tissue (acrolein-lysine adduct) in mice with EAE, which can be reduced through systemic application of acrolein scavenger hydralazine. Furthermore, using this approach we have demonstrated an increase of 3-HPMA in both the urine and serum of MS patients relative to controls. It is expected that this noninvasive acrolein detection could facilitate the investigation of the role of acrolein in the pathology of MS in human. It may also be used to monitor putative therapies aimed at suppressing acrolein levels, reducing severity of symptoms, and slowing progression as previously demonstrated in animal studies.",
keywords = "3-HPMA, Aldehyde, Inflammation, Lipid peroxidation, Oxidative stress",
author = "Melissa Tully and Jonathan Tang and Lingxing Zheng and Glen Acosta and Ran Tian and Lee Hayward and Nicholas Race and David Mattson and Riyi Shi",
year = "2018",
month = "6",
day = "15",
doi = "10.3389/fneur.2018.00420",
language = "English (US)",
volume = "9",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "JUN",

}

TY - JOUR

T1 - Systemic acrolein elevations in mice with experimental autoimmune encephalomyelitis and patients with multiple sclerosis

AU - Tully, Melissa

AU - Tang, Jonathan

AU - Zheng, Lingxing

AU - Acosta, Glen

AU - Tian, Ran

AU - Hayward, Lee

AU - Race, Nicholas

AU - Mattson, David

AU - Shi, Riyi

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, due to the invasive nature of acrolein detection using immunoblotting techniques, the investigation of acrolein in MS has been limited to animal models. Recently, detection of a specific acrolein-glutathione metabolite, 3-HPMA, has been demonstrated in urine, enabling the noninvasive quantification of acrolein for the first time in humans with neurological disorders. In this study, we have demonstrated similar elevated levels of acrolein in both urine (3-HPMA) and in spinal cord tissue (acrolein-lysine adduct) in mice with EAE, which can be reduced through systemic application of acrolein scavenger hydralazine. Furthermore, using this approach we have demonstrated an increase of 3-HPMA in both the urine and serum of MS patients relative to controls. It is expected that this noninvasive acrolein detection could facilitate the investigation of the role of acrolein in the pathology of MS in human. It may also be used to monitor putative therapies aimed at suppressing acrolein levels, reducing severity of symptoms, and slowing progression as previously demonstrated in animal studies.

AB - Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, due to the invasive nature of acrolein detection using immunoblotting techniques, the investigation of acrolein in MS has been limited to animal models. Recently, detection of a specific acrolein-glutathione metabolite, 3-HPMA, has been demonstrated in urine, enabling the noninvasive quantification of acrolein for the first time in humans with neurological disorders. In this study, we have demonstrated similar elevated levels of acrolein in both urine (3-HPMA) and in spinal cord tissue (acrolein-lysine adduct) in mice with EAE, which can be reduced through systemic application of acrolein scavenger hydralazine. Furthermore, using this approach we have demonstrated an increase of 3-HPMA in both the urine and serum of MS patients relative to controls. It is expected that this noninvasive acrolein detection could facilitate the investigation of the role of acrolein in the pathology of MS in human. It may also be used to monitor putative therapies aimed at suppressing acrolein levels, reducing severity of symptoms, and slowing progression as previously demonstrated in animal studies.

KW - 3-HPMA

KW - Aldehyde

KW - Inflammation

KW - Lipid peroxidation

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85048627816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048627816&partnerID=8YFLogxK

U2 - 10.3389/fneur.2018.00420

DO - 10.3389/fneur.2018.00420

M3 - Article

AN - SCOPUS:85048627816

VL - 9

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - JUN

M1 - 420

ER -